Fas antigen derivative

Details Fas antigen derivative Fas antigen derivative

2005-10-11

2005-10-11

Harris, Alana M. (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S001001, C536S018700, C536S022100, C536S023100, C536S023400, C530S300000, C530S350000, C530S385000, C530S386000, C530S387100, C435S069100, C435S320100, C435S325000

Reexamination Certificate

active

06953847

ABSTRACT:
This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes said Fas antigen derivative, a recombinant DNA molecule which contains said DNA sequence, a transformant in which said recombinant DNA molecule is introduced, a method for the production of said Fas antigen derivative, a medicament which contains said novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5874546 (1999-02-01), Nagata et al.
patent: 0 675 200 (1995-04-01), None
patent: 5503009 (1993-05-01), None
patent: 0769914 (1995-03-01), None
patent: 7289266 (1995-11-01), None
patent: 9108298 (1991-06-01), None
patent: 9513293 (1995-05-01), None
Kimura et al. A variant mRNA species encoding a truncated form of fas antigen in the rat liver. Biochemical and Biophysical Research Communication, 198(2): 666-674, Jan. 28, 1994.
Adachi et al. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antgen gene of Ipr mice. Proc. Natl. Sci. USA 90: 1756-1760, Mar. 1993.
Amino acid database, Alignment between Applicants' Seq Id No: 15 and sequences from Biochem. Biophys. Res. Commun. 1994 and Proc. Natl. Acad. Sci. USA, 1993.
Tanaka M. et al., “Expression of the functional soluble form of human Fas ligand in activated lymphocytes”; EMBO Journal, vol. 14, No. 6, pp. 1129-1135 (1995).
Tanaka, M. et al., “Fas ligand in human serum”, Nature Medicine, vol. 2, pp. 317-322 (1996).
Suda, T. et al., “Purification and Characterization of the Fas-ligand that Induces Apoptosis”; J. Exp. Med.; vol. 179, No. 3, pp. 873-879 (1994).
Itoh et al., Cell, vol. 66 (1991) pp. 233-243.
Tanaka et al., The Empo J., vol 14, No. 6 (1995) pp. 1129-1135.
Suda et al., Cell, vol. 75, (1993) pp. 1169-1178.
Ramsdell et al., Eur. J. Immunol., vol. 24 pp. 928-933, 1994.
Ed. Nikkei Baioteku (Nikkei BP Sha) “Nikkei Baio Saishin-Yogo Jiten '91 (in Japanese” p. 550 (1991).

Affiliated with

Also associated with

Rating

Fas antigen derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fas antigen derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fas antigen derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3434727